Project
‹ Go back to overview

State of the Art on TB Drugs

Financer:
European Commission (EC)
Country:
Global
Field of Expertise:
Medical Products, Technologies; Policy/Strategy/DRA; Intellectual Property Rights (TRIPS) and access to medicines
Narrative description of project:
This assignment is part of the Health Advisory Services – HAS project (EUR 1.999.715,00, 10/2014-10/2017, managed by hera consortium). Its identification number within the HAS is HAS 011.
The HAS provides technical support to the European Commission (DEVCO/HQ) and the EU Delegations for a period of three years. DG DEVCO contracted the HAS to support the implementation of its health aid policies and programmes; strengthen the capacity of EU Delegations and DEVCO/HQ; and tackle other issues for which in-house thematic capacity is lacking or insufficient.

DEVCO/HQ had questions about Technology Transfer on production of MDR-TB medicines, specifically whether the Eli Lilly initiative (as published in a White Paper) had been the “right” thing to do. Any comments on the white paper? Should other producers follow a similar path for other products needed in MDR-TB? Or have they done already so? Or even better?